Is Microsatellite Instability Really a Good Prognostic Factor of Colorectal Cancer?

Annals of Coloproctology

Volumn 30, Issue 1, 2014, Pages 28-34

  Shin, Ui Sup ^a   Cho, Sang Sik ^a   Moon, Sun Mi ^a   Park, Sun Hoo ^a   Jee, Sun Hee ^a   Jung, Eun Joo ^b   Hwang, Dae Yong ^b  

^a Korea Cancer Center Hospital   (South Korea)

^b Konkuk University Hospital   (South Korea)

Author keywords

Chemotherapy; Colorectal neoplasms; Microsatellite instability; Prognosis

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ARTICLE; ASCENDING COLON; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLON CANCER; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; FAMILY HISTORY; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; LOADING DRUG DOSE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHENOTYPE; REPEATED DRUG DOSE; TUMOR DIFFERENTIATION;

EID: 84897409470     PISSN: 22879714     EISSN: 22879722     Source Type: Journal    
DOI: 10.3393/ac.2014.30.1.28     Document Type: Article

References (29)

1. Jung KW, Park S, Won YJ, Kong HJ, Lee JY, Park EC, et al. Prediction of cancer incidence and mortality in Korea, 2011. Cancer Res Treat 2011;43:12-8.
2. Fielding LP, Pettigrew N. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the Colorectal Cancer Working Group. Arch Pathol Lab Med 1995;119:1115-21.
3. Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993;260:812-6.
4. Boland CR. Evolution of the nomenclature for the hereditary colorectal cancer syndromes. Fam Cancer 2005;4:211-8.
5. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997;57:808-11.
6. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010;138:2073-87.e3.
7. Jenkins MA, Hayashi S, O'Shea AM, Burgart LJ, Smyrk TC, Shimizu D, et al. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: A population-based study. Gastroenterology 2007;133:48-56.
8. Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000;342:69-77.
9. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609-18.
10. Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol 2010;7:153-62.
11. Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001;344:1196-206.
12. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247-57.
13. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010;28:3219-26.
14. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-57.
15. American Joint Committee on Cancer. Colon and rectum. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2009. p. 143-64.
16. Sinicrope FA. DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer. Nat Rev Clin Oncol 2010;7:174-7.
17. Merok MA, Ahlquist T, Royrvik EC, Tufteland KF, Hektoen M, Sjo OH, et al. Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series. Ann Oncol 2013;24:1274-82.
18. Donada M, Bonin S, Barbazza R, Pettirosso D, Stanta G. Management of stage II colon cancer: The use of molecular biomarkers for adjuvant therapy decision. BMC Gastroenterol 2013;13:36.
19. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109-16.
20. Quasar Collaborative Group, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet 2007;370:2020-9.
21. Jee SH, Moon SM, Shin US, Yang HM, Hwang DY. Effectiveness of adjuvant chemotherapy with 5-FU/leucovorin and prognosis in stage II colon cancer. J Korean Soc Coloproctol 2011;27:322-8.
22. Morris M, Platell C, Iacopetta B. Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy. Clin Cancer Res 2008;14:1413-7.
23. Arnold CN, Goel A, Boland CR. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 2003;106:66-73.
24. Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB, et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999;117:123-31.
25. Fischer F, Baerenfaller K, Jiricny J. 5-Fluorouracil is efficiently removed from DNA by the base excision and mismatch repair systems. Gastroenterology 2007;133:1858-68.
26. Kim ST, Lee J, Park SH, Park JO, Lim HY, Kang WK, et al. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol 2010;66:659-67.
27. Zaanan A, Cuilliere-Dartigues P, Guilloux A, Parc Y, Louvet C, de Gramont A, et al. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol 2010;21:772-80.
28. Oh JR, Kim DW, Lee HS, Lee HE, Lee SM, Jang JH, et al. Microsatellite instability testing in Korean patients with colorectal cancer. Fam Cancer 2012;11:459-66.
29. Sinicrope FA, Sargent DJ. Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol 2009;21:369-73.